You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
郭广昌:复星合作研发新冠mRNA疫苗有效性逾90% 将提速国内落地
阿思达克 11-10 09:21
据内媒报道,复星国际(00656.HK)董事长郭广昌在微博称,复星新冠疫苗在全球的研发合作夥伴BioNTech(BNTX.US)和辉瑞(PFE.US)宣布,根据三期临床试验的初步分析数据,合作研发的mRNA疫苗有效性超90%,而普通流感疫苗也只有70%左右的有效性,远超此前的预期。郭广昌表示,这是科学的胜利,也是全球合作的胜利,标志着在这场面对新冠病毒的战争中已经看到了胜利的曙光。

在复星新冠疫苗全球研发取得突破性进展之际,郭广昌强调,复星将继续与政府监管、审批部门密切沟通协同,希望根据全球研发的进展和数据分析的结果,在符合中国法规的前提下,推动复星新冠疫苗尽早在中国上市使用。

内地方面,据了解,复星旗下复星医药(02196.HK)於今年3月获德国拜恩泰科(BioNTech)授权,在中国大陆及港澳台地区独家开发、注册、商业化基於其专有mRNA技术平台研发的、针对新型冠状病毒的复星新冠疫苗(暂定名「复必泰」),并於7月在国内启动临床试验。目前,复星正与监管部门沟通,力争尽快在国内启动BNT162b2的桥接临床试验。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account